Suzanne Lentzsch

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

Faith E. Davies, Noopur Raje, Teru Hideshima et al. · Blood · 2001 · 905 citations

Medicine, Immunology, Oncology +12

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Shaji Kumar, J H Lee, Juan José Lahuerta et al. · Leukemia · 2011 · 721 citations

Medicine, Hematology, Pharmacotherapy +15

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications

D. Gupta, SP Treon, Yoshihito Shima et al. · Leukemia · 2001 · 555 citations

Medicine, Cancer Biology, Cell Biology +15

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.

Richard LeBlanc, Laurence Catley, Teru Hideshima et al. · PubMed · 2002 · 456 citations

Medicine, Oncology, Pharmacology +13

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Ajai Chari, Attaya Suvannasankha, Joseph W. Fay et al. · Blood · 2017 · 443 citations · Full text

Medicine, Oncology, Pharmacotherapy +12